Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Britain Courts Anthropic Amid US Defense Department Dispute 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NEW YORK, Nov. 10, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Impax Laboratories, Inc. (NASDAQ:IPXL) between February 25, 2014 and November 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/impax-laboratories
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period the Company made false and/or misleading statements and/or failed to disclose that: (a) Impax was engaged in conduct that would cause the antitrust division of the U.S. Department of Justice and the Connecticut Attorney General to conduct extensive investigations of possible collusion of generic drug pricing; (b) the DOJ investigation and the underlying conduct was likely to result in criminal charges against Impax, and possibly its officers and directors, for collusion of generic drug pricing; (c) Impax lacked effective internal controls over financial reporting; and (d) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you suffered a loss in Impax you have until January 9, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
